NF2 and neoplasm: Growth inhibition by rapamycin, an immunosuppressant drug, was demonstrated using an in vitro cell model and a mouse model for NF2 [10] followed by a phase II trial, where everolimus was applied to 10 NF2 patients, which failed to reach the primary endpoint of tumor volume reduction [11].